NPC-REAAD™ ELISA Anti-EBV EA IgA Test (Nasopharyngeal Cancer – REcombinant Antigen-Antibody Detection) is intended for qualitative and semi-quantitative detection of IgA antibodies in human serum. The test utilizes Epstein Barr Virus (EBV) specific proteins to detect a subject’s EA IgA antibody response in serum samples. A number of publications, referenced below, have demonstrated a correlation with EBV antibody response, in particular an IgA response and NPC.
Nasopharyngeal Cancer (NPC) is closely associated with the infection of Epstein Barr Virus (EBV), a virus belonging to the Herpes Virus family. The virus has also been implicated in diseases such as Infectious Mononucleosis (IM), Burkitt’s lymphoma and Hodgkin’s disease.
NPC-REAAD™ uses 4 highly NPC-specific polypeptides generated by DNA recombinant technology to detect the presence of EBV proteins known to be associated with NPC. These polypeptides are known as EA-D, RR-L RR-S and the other is a novel proprietary protein discovered by Restalyst during development of NPC-REAAD™. Studies have shown that their combined specificity to NPC subjects’ serum increased significantly, enabling discrimination of NPC from non-NPC subjects. The Test uses an arbitrary unit of measurement known as REAAD™-units (RU) which can be used for determining the subjects’ NPC risk level.
The number of reagents is sufficient for 5 optimal runs.
Ready to use, 12 strips x 8 microwells coated with capture antibody
Wash Buffer Concentrate
Ready to use Positive Control
Ready to use Negative Control
Sample Conjugate Buffer
Reseal-able bag for unused microwells
See package insert for assay specification details.